Chaojie Liang1, Zining Qi2, Hua Ge3, Chaowei Liang2, Yu Zhang2, Zhimin Wang2, Ruihuan Li2, Jiansheng Guo4. 1. Department of General Surgery, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China. Electronic address: sdyycj90@126.com. 2. Department of General Surgery, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China. 3. Department of Gastrointestinal Surgery, The First People's Hospital of Zunyi, Zunyi Medical University, Zunyi, Guizhou, People's Republic of China. 4. Department of General Surgery, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China. Electronic address: sdyygjs2017@126.com.
Abstract
BACKGROUND AND AIMS: Prostate cancer-associated non-coding RNA transcript-1(PCAT-1), which is a newly discovered long non-coding RNA, is up-regulated in various cancers. We conducted a meta-analysis to assess the clinicopathological and prognostic value of PCAT-1 in patients with malignant tumors. METHODS: A systematic literature search involved PubMed, Medline, Cochrane Library, Web of Science, EMBASE database, Ovid, Chinese CNKI, and the Chinese WanFang database. The role of PCAT-1 in cancers was evaluated by pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs). RESULTS: A total of 1005 patients from nine studies were included in this meta-analysis. High expression of PCAT-1 was associated with depth of infiltration, lymph node metastasis, distant metastasis and TNM stage. However, increased PCAT-1 expression was not related to gender, tumor size and differentiation. Moreover, high PCAT-1 expression was associated with poor overall survival (OS) and disease-free survival (DFS), and the pooled results suggested that PCAT-1 expression can be an independent predictive factor for overall survival. CONCLUSION: This meta-analysis provides evidence that PCAT-1 expression is closely correlated with depth of infiltration, lymph node metastasis, distant metastasis and TNM stage, and that increased PCAT-1 expression may be a potential prognostic biomarker in human cancers. However, more large-scale studies are warranted.
BACKGROUND AND AIMS: Prostate cancer-associated non-coding RNA transcript-1(PCAT-1), which is a newly discovered long non-coding RNA, is up-regulated in various cancers. We conducted a meta-analysis to assess the clinicopathological and prognostic value of PCAT-1 in patients with malignant tumors. METHODS: A systematic literature search involved PubMed, Medline, Cochrane Library, Web of Science, EMBASE database, Ovid, Chinese CNKI, and the Chinese WanFang database. The role of PCAT-1 in cancers was evaluated by pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs). RESULTS: A total of 1005 patients from nine studies were included in this meta-analysis. High expression of PCAT-1 was associated with depth of infiltration, lymph node metastasis, distant metastasis and TNM stage. However, increased PCAT-1 expression was not related to gender, tumor size and differentiation. Moreover, high PCAT-1 expression was associated with poor overall survival (OS) and disease-free survival (DFS), and the pooled results suggested that PCAT-1 expression can be an independent predictive factor for overall survival. CONCLUSION: This meta-analysis provides evidence that PCAT-1 expression is closely correlated with depth of infiltration, lymph node metastasis, distant metastasis and TNM stage, and that increased PCAT-1 expression may be a potential prognostic biomarker in humancancers. However, more large-scale studies are warranted.